To assess the clinical relevance of our findings, a tissue microarray assay (TMA) containing 213 cases (46 non-tumour adjacent and 167 tumour from liver cancer patients) was performed to evaluate the expression of YAP, TFCP2 and CCT3. This evidence concerns the gene CCT3 and neoplasm.